Our Latest News

A place to read about our latest research and press releases.

Adam Parks 8/31/22 Adam Parks 8/31/22

2022.08.31. Innovimmune announces presentation of preclinical Proof of Concept data of oral INV-71 ROR gamma agonist in breast cancer at the ESMO 2022 Congress in Paris

Adam Parks 4/12/22 Adam Parks 4/12/22

2022.04.12. Innovimmune's first-in-class oral INV-88 Macrophage Migration Inhibitory Factor (MIF) inhibitors to be presented at the 2022 American Association for Cancer Research Annual Meeting

$2018.02.16. Single-agent antitumor efficacy of a novel oral INV-25 Liver X receptor (LXR) agonist in a checkpoint-refractory mouse B16-F10 melanoma model presented at the 2018 AAD Meeting in San Diego$

Adam Parks 2/16/18 Adam Parks 2/16/18

2018.02.16. Single-agent antitumor efficacy of a novel oral INV-25 Liver X receptor (LXR) agonist in a checkpoint-refractory mouse B16-F10 melanoma model presented at the 2018 AAD Meeting in San Diego

Adam Parks 9/13/17 Adam Parks 9/13/17

2017.09.13. Preclinical POC data in a mouse Psoriasis model following Topical treatment with small molecule INV-17 ROR gamma inhibitor presented at the 2017 EADV Annual Meeting in Geneva, Switzerland

Adam Parks 3/3/17 Adam Parks 3/3/17

2017.03.03. Psoriasis treatment efficacy of an Oral INV-17 ROR gamma inhibitor in a mouse Imiquimod Psoriasis model presented at the 2017 AAD Annual Meeting in Orlando, FL

Adam Parks 6/11/15 Adam Parks 6/11/15

2015.06.11. Efficacy of INV-17 ROR gamma inhibitor in a mouse Lupus model highlighted at the EULAR 2015 meeting in Rome, Italy

Adam Parks 11/5/14 Adam Parks 11/5/14

2014.11.05. Superior treatment efficacy of novel oral DMARDs: INV-17 ROR gamma & INV-88 MIF inhibitors in murine CIA to be presented at the 2014 ACR Annual Meeting in Boston

Adam Parks 7/25/14 Adam Parks 7/25/14

2014.07.25. Innovimmune awarded NIH NIAID SBIR Phase II $3 Million grant for the development of its oral NCE INV-88 Macrophage Migration Inhibitory Factor (MIF) inhibitors for Autoimmune Diseases

Adam Parks 5/15/14 Adam Parks 5/15/14

2014.05.15. INV-17 ROR gamma inhibitor portfolio in preclinical development stage

Adam Parks 2/17/14 Adam Parks 2/17/14

2014.02.17. INV-17 ROR gamma Autoimmune Disease Preclinical POC

Adam Parks 1/21/14 Adam Parks 1/21/14

2014.01.21. Innovimmune INV-17 ROR gamma inhibitor prevents Multiple Sclerosis in mice

Adam Parks 10/1/12 Adam Parks 10/1/12

2012.10.01. Innovimmune: Structuring Immunotherapies

Adam Parks 8/7/12 Adam Parks 8/7/12

2012.08.07. Innovimmune featured in Xconomy

Adam Parks 6/13/12 Adam Parks 6/13/12

2012.06.13. Innovimmune awarded NIH NIAID SBIR $0.6 Million grant for the development of its oral NCE INV-88 Macrophage Migration Inhibitory Factor (MIF) inhibitors for Autoimmune Diseases

Our Latest News

Partnering, advancing together